A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

BACKGROUND: To assess the efficacy and safety of a combination therapy involving fimasartan, amlodipine, and rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond to fimasartan monotherapy. METHODS: This phase III, randomized, double-blind, multicenter study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Eun-Seok, Lim, Sang Wook, Kim, Seok-Yeon, Yang, Hyoung-Mo, Kim, Moo Hyun, Rhee, Moo-Yong, Han, Seung Hwan, Shin, Jinho, Kim, Kwang-il, Jeong, Jin-Ok, Sung, Ki Chul, Hong, Geu Ru, Kim, Hyung-Seop, Kwon, Kihwan, Kang, Tae-Soo, Lee, Hae-Young, Han, Su-Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714199/
https://www.ncbi.nlm.nih.gov/pubmed/36451242
http://dx.doi.org/10.1186/s40885-022-00223-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714199/
https://www.ncbi.nlm.nih.gov/pubmed/36451242
http://dx.doi.org/10.1186/s40885-022-00223-4

Ejemplares similares